Key result
Multimodal imaging proves crucial for diagnosing and risk stratifying potentially fatal ICI myocarditis.
Why the study?
ICI myocarditis is a rare but potentially fatal immune-related adverse event, and diagnosing it can be intricate due to its atypical presentations.
Multimodal imaging is crucial for the diagnosis and risk stratification of immune checkpoint inhibitor myocarditis.
Answers are grounded in this paper and cite their sources.
May support multimodal imaging in ICI myocarditis; leaves optimal protocols and prospective validation open.
Immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of cancer treatment and are increasingly used either as monotherapy or in combination with other ICIs, chemotherapy, and molecularly targeted agents. ICI myocarditis is a rare but potentially fatal irAE associated with the use of ICI characterized by T-cell mediated cardiomyocyte death. Diagnosing ICI myocarditis can be intricate as its atypical presentations. Multimodal imaging plays a crucial role in the diagnosis and risk stratification of ICI myocarditis. Current management strategies for ICI myocarditis include corticosteroids and immunosuppressants. Multidisciplinary collaboration is vital in these cases-combining oncology expertise with cardiology insights.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2025) conducted a review in Immune Checkpoint Inhibitor Myocarditis. Multimodal imaging was evaluated. Multimodal imaging plays a crucial role in the diagnosis and risk stratification of immune checkpoint inhibitor myocarditis, a rare but potentially fatal adverse event.
Synapse has enriched 10 related papers. Consider them for comparative context: